US7754748B2 - Method for treating obesity - Google Patents
Method for treating obesity Download PDFInfo
- Publication number
- US7754748B2 US7754748B2 US12/205,769 US20576908A US7754748B2 US 7754748 B2 US7754748 B2 US 7754748B2 US 20576908 A US20576908 A US 20576908A US 7754748 B2 US7754748 B2 US 7754748B2
- Authority
- US
- United States
- Prior art keywords
- zonisamide
- weight
- subject
- subjects
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
- zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
- Zonisamide (ZONEGRAN®) is a marketed antiepileptic drug (AED).
- AED antiepileptic drug
- zonisamide is believed to be related to its sodium and calcium channel (T-type) channel blocking activity (Oommen and Matthews, Clin. Neuropharmacol. 22:192-200 (1999)).
- This drug is also known to exert dopaminergic (Okada et al, Epilepsy Res. 22:193-205 (1995)) as well as dose-dependent biphasic serotonergic activity (Okada et al, Epilepsy Res. 34:187-197 (1999)).
- Topiramate is an AED that has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy in treating simple and complex partial seizures and secondarily generalized seizures (Faught et al, Epilepsia 36(S4):33 (1995); Sachdeo et al, Epilepsia 36(S4):33 (1995)). It is currently marketed as adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures.
- Bupropion marketed as an antidepressant, has a pharmacological action dissimilar to that of zonisamide or topiramate. Bupropion has been shown to cause significant weight loss in patients presenting with primary obesity (Gadde et al, Obes. Res. 9(9):544 (2001)).
- the present invention results, at least in part, from studies demonstrating that zonisamide is more effective than placebo for weight loss in obese subjects.
- zonisamide or other weight-loss promoting anticonvulsant
- bupropion or other compound that enhances monoamine (e.g., serotonin, norepinephrine and/or dopamine) turnover in the brain via uptake inhibition or other mechanism) provides an effective treatment for obesity with few side effects.
- the present invention relates generally to obesity. More specifically, the invention relates to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
- zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
- FIG. 1 Disposition of study subjects.
- LOCF last observation-carried-forward
- the present invention relates to a method of treating obesity in an animal.
- the invention further relates to a method of minimizing metabolic risk factors associated with obesity, such as hypertension, diabetes and dyslipidaemia.
- the methods comprise administering to an animal in need of such treatment an effective amount of zonisamide or other weight-loss promoting anticonvulsant.
- the methods comprise administering a combination of zonisamide or topiramate, or other weight-loss promoting anticonvulsant (including agents that block kainate/AMPA (D,L- ⁇ -amino-3-hydroxy-5-methyl-isoxazole propionic acid) subtype glutamate receptors), and bupropion, or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism, in effective amounts.
- zonisamide or topiramate or other weight-loss promoting anticonvulsant (including agents that block kainate/AMPA (D,L- ⁇ -amino-3-hydroxy-5-methyl-isoxazole propionic acid) subtype glutamate receptors)
- bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism, in effective amounts.
- Preferred active agents for use in the present invention include zonisamide or topiramate (and pharmaceutically acceptable salts thereof), however, other methane-sulfonamide derivatives, such as those described in U.S. Pat. No. 4,172,896, or other sulfamates (including sulfamate-substituted monosaccharides), such as those described in U.S. Pat. No. 4,513,006, can also be used. While the use of bupropion is also preferred, compounds disclosed in U.S. Pat. Nos. 3,819,706 and 3,885,046 can be used, as can other compounds that enhance the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism (e.g., Atomoxetine or Reboxetine).
- methane-sulfonamide derivatives such as those described in U.S. Pat. No. 4,172,896, or other sulfamates (including sulfamate-substituted monos
- the term “obesity” includes both excess body weight and excess adipose tissue mass in an animal.
- An obese individual is one (e.g., 21-50 years old) having a body mass index of ⁇ 30 kg/m 2 . While the animal is typically a human, the invention encompasses the treatment of non-human mammals.
- the amount of active agent(s) can vary with the patient, the route of administration and the result sought. Optimum dosing regimens for particular patients can be readily determined by one skilled in the art.
- the dose can be from about 25 mg to about 800 mg per day, generally given once per day or divided (e.g., equally) into multiple doses.
- the dose is from about 100 mg to about 600 mg per day, more preferably, the dose is from about 200 mg to about 400 mg per day. However, it may be necessary to use dosages outside these ranges.
- the daily dose of, for example, zonisamide can be from about 25 mg to about 800 mg, preferably from about 100 mg to about 600 mg, more preferably from about 200 mg to about 400 mg.
- the daily dose of topiramate can be from about 25 mg to about 1600 mg, preferably from about 50 mg to about 600 mg, more preferably from about 100 mg to about 400 mg.
- the daily dose of bupropion used can be from about 25 mg to about 600 mg, preferably from about 50 mg or about 150 mg to about 450 mg.
- the doses can be given once per day or divided (e.g., equally) into multiple doses. It may be necessary to use dosages outside these ranges.
- the ratio of zonisamide (or topiramate) to bupropion can range, for example, from about 2:1 to about 1:2.
- the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- the active agent(s) e.g., zonisamide alone or in combination with bupropion
- the active agent(s) can be administered in any convenient manner, such as orally, sublingually, rectally, parentally (including subcutaneously, intrathecharly, intramuscularly and intravenously), or transdermally.
- the most preferred route of administration is the oral route.
- the active agents of the invention can be administered in the form of a pharmaceutical composition or compositions that contain one or both in an admixture with a pharmaceutical carrier.
- the pharmaceutical composition can be in dosage unit form such as tablet, capsule, sprinkle capsule, granule, powder, syrup, suppository, injection or the like. Sustained released formulations can also be used.
- the composition can also be present in a transdermal delivery system, e.g., a skin patch.
- the combination of, for example, zonisamide or topiramate and bupropion is an effective treatment for obesity and provides an effective means of minimizing metabolic risks associated with obesity.
- the combination can be more effective than, for example, zonisamide or topiramate treatment alone and with fewer side effects.
- zonisamide or topiramate can be offset by insomnia, activation, psychomotor agitation and antidepressant effects of, for example, bupropion.
- zonisamide or topiramate for example, can reduce the seizure risk associated with, for example, bupropion.
- Lower doses of both types of medication can be used in the combination treatment, thereby further reducing the overall side effect burden.
- Inclusion criteria were: male or female, aged 21-50 years, with body mass index (BMI) of ⁇ 30 kg/m 2 .
- Exclusion criteria were: obesity of a known endocrine origin, such as hypothyroidism and Cushing's syndrome; serious/unstable medical or psychiatric illness; current major psychiatric disorder; current drug or alcohol abuse; history of or current kidney disease or renal calculi; significant liver disease; uncontrolled hypertension; current diabetes mellitus (DM), type 1 or 2 DM receiving pharmacotherapy; untreated or uncontrolled thyroid disease; weight loss or gain greater than four kilograms in past three months; history of obesity surgery; current or recent use of any weight loss medications, herbs, or supplements; current or recent use of drugs, herbs, or dietary supplements known to significantly affect body weight; concomitant medications that significantly affect P450 3A4 hepatic microsomal enzymes; hypersensitivity to sulfonamides; women of child-bearing age not adhering to an acceptable form of contraception; pregnant or breast-feeding women; and, subjects judged to be unable to follow instructions and study procedures.
- the subjects were randomized in a 1:1 ratio to receive zonisamide or placebo capsules.
- Study medication was dispensed under blinded conditions through computer-based randomization.
- the randomization was generated using a random number table with a block size of ten. There was no stratification by gender or other demographics.
- the study investigators were blind to the “blocking” method used by the pharmacy.
- the treatment assignment codes were not available to the investigators until all subjects completed the acute phase, the data were entered, and the database for this phase was locked, meaning that no further changes could be made to the data.
- the study medication was dispensed in the form of capsules. Each capsule contained either 100 milligrams zonisamide or placebo. The capsules were made to look identical. The dose escalation was as follows: one capsule (zonisamide 100 mg or placebo) every evening for the first 2 weeks; two capsules (zonisamide 200 mg or placebo) every evening during Weeks 3 and 4; three capsules (zonisamide 300 mg or placebo) every evening during Weeks 5 and 6; and, four capsules (zonisamide 400 mg or placebo) every evening from Week 7 onward. At Week 12, the dose could be increased further to six capsules (zonisamide 600 mg or placebo) every evening for subjects who had not lost at least 5% of their initial body weight.
- Subjects in both treatment groups were instructed to follow an individual diet that was 500 Kcal/day less than what they needed to maintain their weight.
- the prescribed diet based on eating a variety of foods from the Food Guide Pyramid, emphasized decreasing portions, eating more fruits and vegetables, and drinking 8 cups of water each day.
- Increased physical activity was also encouraged for subjects in both groups.
- Subjects were asked to record their dietary intake including portion sizes in food diaries, which were provided to them.
- a registered dietician reviewed food diaries and provided counseling to all subjects. Subjects were encouraged to make healthy changes in their diets and physical activity that could be maintained after the completion of the study.
- Subjects were seen at weeks 0, 2, 4, 8, 12, and 16 in the acute phase, and every four weeks in the extension phase. During each visit, the following assessments were performed: blood pressure, heart rate, weight, dietary compliance, medication accountability and tolerability, and adverse effects. Body weight was measured on a calibrated electronic scale to the nearest 0.1 kilogram. A registered dietitian reviewed food diaries and assessed dietary compliance. Adverse effects were gathered via spontaneous reporting by subjects as well as open-ended inquiries by the clinicians. Reportable adverse effects were new symptoms or illnesses that emerged during treatment or those that had an increase in severity compared with baseline.
- the IWQOL is a self-report measure with 74 items that assess the perceived effect of weight on quality of life in the following domains (subscales)—health, social/interpersonal life, work, mobility, self-esteem, sexual life, activities of daily living, and eating (comfort with food). Improvement with treatment is reflected by decreasing scores on all the subscales with the exception of the eating (comfort with food) subscale, which is expected to show less comfort around food with effective treatment.
- Body composition fat and lean masses
- BMD bone mineral density
- Body weight was the primary end point. Examined were the absolute change in weight, percent change in weight, and the number of subjects in each group that achieved weight losses of 5% and 10%. Secondary outcome measures included heart rate, blood pressure, frequency of adverse effects, fasting electrolytes and lipids, waist measurement, VAS-C, IWQOL, body composition and BMD.
- Weight change during the study was assessed in terms of actual weight change over the six study intervals using multivariable regression methodology, and as a dichotomous outcome of ‘response,’ i.e., 5% weight loss at Week 16, and 5% and 10% weight loss at Week 32.
- the proxy variables denoting response status were tested across treatment conditions again using Fisher's exact test.
- Three multivariable regression analyses were conducted. In the first, body weight at each time point was modeled using a random effects growth curve model. Heuristically, the model fits a regression line for each subject using available data points, thus maximizing use of actual data.
- body weights were regressed as above with missing observations carried forward from the last recorded weight based on an intent-to-treat approach (LOCF).
- LOCF intent-to-treat approach
- the final model was restricted to the subset of respondents with no missing data (completers). All models included covariates for gender and BMI as well as proxy variables denoting treatment condition, time, and a term for the interaction of treatment with time; age race, and percent body fat at baseline were not significantly associated with weight loss and, hence, excluded from the above models.
- the second general area of sampled quality of life indicators including activities of daily living, appetite, esteem, health, interpersonal relations, mobility, sex, and work using the IWQOL Scale; repeated measurements were taken at baseline, Week 8, and Week 16).
- the final set of secondary analyses sampled hunger and appetite using the Visual Analogue Scale for Hunger and Food Cravings. Categories sampled included sweets, breads, salts, fats, meats, sodas, and overall hunger. Measurements were sampled at baseline, Week 8, and Week 16.
- the prescribed mean highest daily dose of zonisamide was 427 (29) mg, corresponding to 4.27 capsules, whereas the placebo group received 5.00 capsules (corresponding to 500 mg).
- the curves for weight change as a percent weight loss over the 16-week duration for zonisamide and placebo groups are shown in FIG. 2 for subjects in the intent-to-treat (ITT) analysis with LOCF.
- results from random coefficient regression analyses supported differential weight loss for zonisamide-treated subjects. Regardless of imputation procedure, the drug-by-time interaction differed significantly from zero in all models.
- the estimated regression coefficient associated with the interaction term predicted weight loss per week in excess of 0.3 kg over the course of the study; complimentary values for the other two models were 0.29 kg/wk using LOCF intent-to-treat imputation, and 0.21 kg/wk as estimated from the model based only on complete-data subjects.
- female gender was associated with significantly lower weight levels, while higher BMI scores were associated with increasing weight levels, again irrespective of model.
- Heart rate decreased by an average of approximately 2 beats/min in the overall sample (p ⁇ 0.0007) although there was no difference between the groups.
- Systolic and diastolic blood pressure readings did not change by four months.
- Diastolic blood pressure decreased with ZON treatment, but not with PBO (82.5 [1.8] mmHg to 79.7 [1.2] mmHg vs. 82.5 [1.8] mmHg to 82.2 [1.1] mmHg; time ⁇ treatment: F 1,34 1.99; p ⁇ 0.0403). Heart rate showed no significant change with either treatment.
- Bone mineral density at lumbar vertebrae did not change over time in either group.
- Total bone mineral density showed a small, but statistically significant (p ⁇ 0.017) increase in both groups although not clinically significant; there was no difference between the groups in this regard.
- Zonisamide was generally well tolerated. Fatigue was the only adverse effect that occurred at a higher frequency than with placebo treatment. Although not observed frequently in this study, the following adverse effects occurred frequently in the zonisamide epilepsy trials: dizziness, cognitive impairment, and somnolence. Zonisamide is a sulfonamide; there is a potential for hypersensitivity reactions. Serious hematologic events have also been reported. The risk of kidney stones also needs recognition. For the duration of treatment in this study (approximately 8 months), the rate of occurrence of kidney stones with zonisamide therapy is estimated to be 62.5 per 1000 patient-years of exposure. Consistent with data from epilepsy trials, an increase in serum creatinine was noted with zonisamide therapy, but not with placebo. Whereas the increase (approximately 16% increase) was significant, there was no further increase in the extension phase; no value exceeded the upper limit of normal range and there were no clinical events associated with the increase.
- the dose of bupropion was increased to 200 mg a day.
- the patient had lost 8.2 lbs and reported no side effects. She reported that she felt “full” after eating small portions of food, and had more energy. She had lost over 35 lbs over ten months on the combination therapy with no side effects.
- bupropion was added at 150 mg/d. After 14 weeks of combined therapy, the patient lost 9.4 lb with no adverse effects.
Abstract
Description
TABLE 1 |
Baseline Characteristics of the Subjects |
Zonisamide | Placebo | |||
Characteristic | (n = 30) | (n = 30) | ||
Age, yrs | 37.5 (1.3) | 36.4 (1.6) | ||
Sex, No. | ||||
|
5 | 0 | ||
Women | 25 | 30 | ||
Race, No. | ||||
|
12 | 17 | ||
White | 18 | 13 | ||
Weight, kg | 98.2 (2.5) | 97.8 (2.6) | ||
BMI, kg/m2 | 35.4 (0.7) | 37.2 (0.8) | ||
Body fat, % | 40.8 (0.9) | 42.6 (0.8) | ||
Age, weight, BMI and body fat are presented as group means (SE). | ||||
BMI denotes body mass index, defined as weight in kilograms divided by the square of height in meters. |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/205,769 US7754748B2 (en) | 2002-05-17 | 2008-09-05 | Method for treating obesity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38087402P | 2002-05-17 | 2002-05-17 | |
US10/440,404 US7109198B2 (en) | 2002-05-17 | 2003-05-19 | Method for treating obesity |
US10/830,071 US7425571B2 (en) | 2002-05-17 | 2004-04-23 | Method for treating obesity |
US12/205,769 US7754748B2 (en) | 2002-05-17 | 2008-09-05 | Method for treating obesity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/830,071 Continuation US7425571B2 (en) | 2002-05-17 | 2004-04-23 | Method for treating obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080319036A1 US20080319036A1 (en) | 2008-12-25 |
US7754748B2 true US7754748B2 (en) | 2010-07-13 |
Family
ID=29550030
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/440,404 Expired - Lifetime US7109198B2 (en) | 2002-05-17 | 2003-05-19 | Method for treating obesity |
US10/830,071 Expired - Lifetime US7425571B2 (en) | 2002-05-17 | 2004-04-23 | Method for treating obesity |
US11/059,027 Abandoned US20050143322A1 (en) | 2002-05-17 | 2005-02-15 | Method for treating obesity |
US11/058,981 Abandoned US20050137144A1 (en) | 2002-05-17 | 2005-02-15 | Method for treating obesity |
US11/222,135 Abandoned US20060009514A1 (en) | 2002-05-17 | 2005-09-07 | Method for treating obesity |
US11/381,990 Abandoned US20080188476A1 (en) | 2002-05-17 | 2006-05-05 | Method for treating obesity |
US12/205,769 Expired - Fee Related US7754748B2 (en) | 2002-05-17 | 2008-09-05 | Method for treating obesity |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/440,404 Expired - Lifetime US7109198B2 (en) | 2002-05-17 | 2003-05-19 | Method for treating obesity |
US10/830,071 Expired - Lifetime US7425571B2 (en) | 2002-05-17 | 2004-04-23 | Method for treating obesity |
US11/059,027 Abandoned US20050143322A1 (en) | 2002-05-17 | 2005-02-15 | Method for treating obesity |
US11/058,981 Abandoned US20050137144A1 (en) | 2002-05-17 | 2005-02-15 | Method for treating obesity |
US11/222,135 Abandoned US20060009514A1 (en) | 2002-05-17 | 2005-09-07 | Method for treating obesity |
US11/381,990 Abandoned US20080188476A1 (en) | 2002-05-17 | 2006-05-05 | Method for treating obesity |
Country Status (11)
Country | Link |
---|---|
US (7) | US7109198B2 (en) |
EP (3) | EP2301537A1 (en) |
JP (1) | JP4545584B2 (en) |
KR (2) | KR20110043664A (en) |
CN (1) | CN1320886C (en) |
AU (1) | AU2003231788B2 (en) |
CA (1) | CA2483464C (en) |
HK (1) | HK1074778A1 (en) |
MX (1) | MXPA04011203A (en) |
RU (1) | RU2341259C2 (en) |
WO (1) | WO2003097046A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
US8722085B2 (en) | 2006-11-09 | 2014-05-13 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
US8815889B2 (en) | 2005-11-22 | 2014-08-26 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US9801875B2 (en) | 2013-12-06 | 2017-10-31 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20190290618A1 (en) * | 2002-05-17 | 2019-09-26 | Duke University | Method for Treating Obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
KR20110043664A (en) * | 2002-05-17 | 2011-04-27 | 듀크 유니버시티 | Method for treating obesity |
US20190262318A1 (en) * | 2002-05-17 | 2019-08-29 | Duke University | Method for Treating Obesity |
US20050059718A1 (en) * | 2003-02-21 | 2005-03-17 | Hayato Miyachi | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050043704A1 (en) * | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050043773A1 (en) * | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050154032A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154033A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154034A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154036A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154037A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
SE0400378D0 (en) * | 2004-02-17 | 2004-02-17 | Jan Hedner | Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
JP2007536229A (en) * | 2004-05-03 | 2007-12-13 | デューク・ユニバーシティー | Composition for acting on weight loss |
US20060153934A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and magnesium |
EP1890700A2 (en) * | 2005-05-31 | 2008-02-27 | Orexigen Therapeutics, Inc. | Methods and compositions for managing psychotic disorders |
NZ561375A (en) * | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
CA2619042C (en) | 2005-08-17 | 2011-03-15 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatment of kidney disease |
US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
ES2383330T3 (en) * | 2005-11-28 | 2012-06-20 | Orexigen Therapeutics, Inc. | Zonisamide Sustained Release Formulation |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
WO2009152152A1 (en) * | 2008-06-09 | 2009-12-17 | Amarillo Biosciences, Inc. | Treatment of obesity with an interferon |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
US20110269828A1 (en) * | 2008-12-30 | 2011-11-03 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating and preventing weight-related disorders in companion animals |
US8383638B2 (en) * | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
US8440655B2 (en) | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
RU2017129378A (en) | 2011-07-15 | 2019-02-04 | Нусерт Сайенсиз, Инк. | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC WAYS |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
CA2891335C (en) | 2012-11-13 | 2021-05-04 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
AU2014207707B2 (en) | 2013-01-15 | 2018-11-01 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9585876B2 (en) | 2013-03-15 | 2017-03-07 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Citations (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3819706A (en) | 1969-12-04 | 1974-06-25 | Burroughs Wellcome Co | Meta chloro substituted-alpha-butylamino-propiophenones |
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
US4089855A (en) | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US4855306A (en) | 1987-04-10 | 1989-08-08 | Sandoz Ltd. | Uses of dopamine receptor agonists |
WO1990013294A1 (en) | 1989-05-09 | 1990-11-15 | Whitby Research, Inc. | A method of reducing body weight and food intake using a dopamine d2 receptor agonist |
EP0442769A2 (en) | 1990-01-19 | 1991-08-21 | Fondation Nationale De Transfusion Sanguine | Compounds destined for encapsulation in erythrocytes, new derivatives of naloxone and naltrexone |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5426112A (en) | 1984-04-09 | 1995-06-20 | Scully, Scott, Murphy & Presser, P.C. | Growth regulation and related applications of opioid antagonists |
US5427798A (en) | 1992-08-14 | 1995-06-27 | Burroughs Wellcome Co. | Controlled sustained release tablets containing bupropion |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
WO1996009047A1 (en) | 1994-09-19 | 1996-03-28 | The Du Pont Merck Pharmaceutical Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5731000A (en) | 1993-07-30 | 1998-03-24 | Glaxo Wellcome Inc. | Stabilized pharmaceutical composition containing bupropion |
WO1999037305A1 (en) | 1998-01-21 | 1999-07-29 | Glaxo Group Limited | Pharmaceutically active morpholinol |
US6004970A (en) | 1996-03-13 | 1999-12-21 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6071537A (en) | 1996-06-28 | 2000-06-06 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating obesity |
US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
WO2000050020A2 (en) | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000051546A2 (en) | 1999-03-01 | 2000-09-08 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
WO2000076493A1 (en) | 1999-06-14 | 2000-12-21 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
WO2001001973A2 (en) | 1999-07-01 | 2001-01-11 | Pharmacia & Upjohn Company | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US6197827B1 (en) | 1997-10-03 | 2001-03-06 | Cary Medical Corporation | Nicotine addiction treatment |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
WO2001026641A2 (en) | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
US6245766B1 (en) | 1997-12-18 | 2001-06-12 | Pfizer Inc | Method of treating psychiatric conditions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
WO2001062257A2 (en) | 2000-02-22 | 2001-08-30 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
US6342515B1 (en) * | 1997-12-26 | 2002-01-29 | Dainippon Pharmaceutical Co., Ltd. | Remedy for neurodegenerative diseases |
US6344474B1 (en) | 1997-01-28 | 2002-02-05 | Sanofi-Synthelabo | Use of central cannabinoid receptor antagonists for regulating appetence |
WO2002009694A1 (en) | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
US20020025972A1 (en) | 1999-10-04 | 2002-02-28 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US20020037836A1 (en) | 2000-09-18 | 2002-03-28 | Henriksen Dennis Bang | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US20020090615A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US6437147B1 (en) | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
US6441038B1 (en) | 1999-10-12 | 2002-08-27 | Laxdale Limited | Treatment of fatigue, head injury and stroke |
US6506799B1 (en) | 1999-04-01 | 2003-01-14 | Esperion Therapeutics, Inc. | Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds |
WO2003013524A1 (en) | 2001-08-09 | 2003-02-20 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20030055008A1 (en) | 1999-05-24 | 2003-03-20 | Marcotte David B. | Anticonvulsant derivatives useful in treating psychosis |
US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
US20030144271A1 (en) | 2000-01-22 | 2003-07-31 | Albert Shulman | Methods for the treatment of substance abuse |
WO2003092682A1 (en) | 2002-05-06 | 2003-11-13 | Eisai Co., Ltd. | Zonisamide use in obesity and eating disorders |
WO2003097046A1 (en) | 2002-05-17 | 2003-11-27 | Duke University | Method for treating obesity |
US20040002462A1 (en) | 1999-06-14 | 2004-01-01 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
WO2004009015A2 (en) | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
US6686337B2 (en) | 2000-10-30 | 2004-02-03 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
WO2004024096A2 (en) | 2002-09-13 | 2004-03-25 | Eisai Co., Ltd. | Method of treating tremors |
US6713488B2 (en) | 2000-03-15 | 2004-03-30 | Sadee Wolfgang | Neutral antagonists and use thereof in treating drug abuse |
US20040106576A1 (en) | 1999-04-06 | 2004-06-03 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
WO2004050020A2 (en) | 2002-11-27 | 2004-06-17 | Simon David L | Improved opioid pharmaceutical compositions |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
WO2004110368A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
WO2005000217A2 (en) | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
WO2005049043A1 (en) | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
US6905708B2 (en) | 1999-02-26 | 2005-06-14 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
US20050154002A1 (en) | 2003-07-23 | 2005-07-14 | Crooks Peter A. | Novel oral bioavailable prodrugs |
US20050181070A1 (en) | 2004-01-13 | 2005-08-18 | Gadde Kishore M. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20050277579A1 (en) | 2004-05-03 | 2005-12-15 | Ranga Krishnan | Compositions for affecting weight loss |
WO2006017504A1 (en) | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
US20060079501A1 (en) | 2004-01-13 | 2006-04-13 | Krishnan K R R | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060100205A1 (en) | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9514A (en) * | 1853-01-04 | Improvement in self-winding telegraphic registers | ||
US58293A (en) * | 1866-09-25 | Improved lady s-saddle tree | ||
US215552A (en) * | 1879-05-20 | Improvement in gar-couplings | ||
US254208A (en) * | 1882-02-28 | Geoegb e | ||
US2462A (en) * | 1842-02-21 | Worked buttons on the heads | ||
US122033A (en) * | 1871-12-19 | Improvement in rotary engines | ||
US154002A (en) * | 1874-08-11 | Improvement in electric telegraphs | ||
US106576A (en) * | 1870-08-23 | Improvement in washing-machines | ||
US181070A (en) * | 1876-08-15 | Improvement in burglar-proof gratings | ||
US160750A (en) * | 1875-03-16 | Improvement in grain-separators | ||
US137144A (en) * | 1873-03-25 | Improvement in stop-cocks | ||
US143322A (en) * | 1873-09-30 | blake | ||
US55008A (en) * | 1866-05-22 | Improved clothes-sprinkler | ||
US33965A (en) * | 1861-12-17 | Improvement in rifle-sights | ||
US144174A (en) * | 1873-10-28 | Improvement in steam-engine valve-gears | ||
US100205A (en) * | 1870-02-22 | Improvement in furnaces | ||
US277579A (en) * | 1883-05-15 | Axle-skein | ||
US26986A (en) * | 1860-01-31 | Mortising-machine | ||
US142290A (en) * | 1873-08-26 | Improvement in trimming attachments for sewing-machines | ||
US79501A (en) * | 1868-06-30 | Jambs righey | ||
US5713488A (en) * | 1996-01-24 | 1998-02-03 | Farrugia; John V. | Condom dispenser |
US6048322A (en) * | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6267995B1 (en) | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
US6481031B1 (en) * | 2001-11-14 | 2002-11-19 | In Mo Hwang | Pillow oriented for comfort in varying sleeping positions |
KR100965580B1 (en) * | 2003-08-21 | 2010-06-23 | 엘지디스플레이 주식회사 | Liquid crystal display apparatus and driving method thereof |
EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | Methods for reducing the side effects associated with mirtazapine treatment |
US7346233B2 (en) * | 2005-02-14 | 2008-03-18 | Corning Incorporated | Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s) |
-
2003
- 2003-05-19 KR KR1020117003379A patent/KR20110043664A/en not_active Application Discontinuation
- 2003-05-19 EP EP10185789A patent/EP2301537A1/en not_active Ceased
- 2003-05-19 MX MXPA04011203A patent/MXPA04011203A/en active IP Right Grant
- 2003-05-19 WO PCT/US2003/015703 patent/WO2003097046A1/en active Application Filing
- 2003-05-19 KR KR1020047018476A patent/KR101072885B1/en active IP Right Grant
- 2003-05-19 RU RU2004131636/14A patent/RU2341259C2/en active
- 2003-05-19 AU AU2003231788A patent/AU2003231788B2/en not_active Expired
- 2003-05-19 EP EP16178084.6A patent/EP3173082A1/en not_active Withdrawn
- 2003-05-19 US US10/440,404 patent/US7109198B2/en not_active Expired - Lifetime
- 2003-05-19 CA CA2483464A patent/CA2483464C/en not_active Expired - Lifetime
- 2003-05-19 JP JP2004505045A patent/JP4545584B2/en not_active Expired - Fee Related
- 2003-05-19 CN CNB038112299A patent/CN1320886C/en not_active Expired - Lifetime
- 2003-05-19 EP EP03753096.1A patent/EP1505967B1/en not_active Expired - Lifetime
-
2004
- 2004-04-23 US US10/830,071 patent/US7425571B2/en not_active Expired - Lifetime
-
2005
- 2005-02-15 US US11/059,027 patent/US20050143322A1/en not_active Abandoned
- 2005-02-15 US US11/058,981 patent/US20050137144A1/en not_active Abandoned
- 2005-08-15 HK HK05107036.6A patent/HK1074778A1/en not_active IP Right Cessation
- 2005-09-07 US US11/222,135 patent/US20060009514A1/en not_active Abandoned
-
2006
- 2006-05-05 US US11/381,990 patent/US20080188476A1/en not_active Abandoned
-
2008
- 2008-09-05 US US12/205,769 patent/US7754748B2/en not_active Expired - Fee Related
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3819706A (en) | 1969-12-04 | 1974-06-25 | Burroughs Wellcome Co | Meta chloro substituted-alpha-butylamino-propiophenones |
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
US4089855A (en) | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5426112A (en) | 1984-04-09 | 1995-06-20 | Scully, Scott, Murphy & Presser, P.C. | Growth regulation and related applications of opioid antagonists |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US4855306A (en) | 1987-04-10 | 1989-08-08 | Sandoz Ltd. | Uses of dopamine receptor agonists |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
WO1990013294A1 (en) | 1989-05-09 | 1990-11-15 | Whitby Research, Inc. | A method of reducing body weight and food intake using a dopamine d2 receptor agonist |
EP0442769A2 (en) | 1990-01-19 | 1991-08-21 | Fondation Nationale De Transfusion Sanguine | Compounds destined for encapsulation in erythrocytes, new derivatives of naloxone and naltrexone |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5427798A (en) | 1992-08-14 | 1995-06-27 | Burroughs Wellcome Co. | Controlled sustained release tablets containing bupropion |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5817665A (en) | 1993-03-02 | 1998-10-06 | John S. Nagle | Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor |
US6034091A (en) | 1993-03-02 | 2000-03-07 | John S. Nagle | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5856332A (en) | 1993-03-02 | 1999-01-05 | John S. Nagle, Esq. | Composition and method of treating depression using a pentacyclic nucleus opioid antagonist in combination with a tricyclic antidepressant |
US5763493A (en) | 1993-07-30 | 1998-06-09 | Glaxo Wellcome Inc. | Stabilized pharmaceutical |
US5731000A (en) | 1993-07-30 | 1998-03-24 | Glaxo Wellcome Inc. | Stabilized pharmaceutical composition containing bupropion |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
US5958962A (en) | 1994-09-19 | 1999-09-28 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
WO1996009047A1 (en) | 1994-09-19 | 1996-03-28 | The Du Pont Merck Pharmaceutical Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6004970A (en) | 1996-03-13 | 1999-12-21 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US6541478B1 (en) | 1996-03-13 | 2003-04-01 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
RU2214241C2 (en) | 1996-06-28 | 2003-10-20 | Орто-Макнейл Фармасьютикал, Инк. | Method for treatment of obesity and method for inducing weight loss in mammals |
US6071537A (en) | 1996-06-28 | 2000-06-06 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating obesity |
US6344474B1 (en) | 1997-01-28 | 2002-02-05 | Sanofi-Synthelabo | Use of central cannabinoid receptor antagonists for regulating appetence |
US20050026986A1 (en) | 1997-01-28 | 2005-02-03 | Jeanne Maruani | Use of central cannabinoid receptor antagonists for the preparation of drugs |
US6197827B1 (en) | 1997-10-03 | 2001-03-06 | Cary Medical Corporation | Nicotine addiction treatment |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
US20010025038A1 (en) | 1997-10-28 | 2001-09-27 | Coffin Vicki L. | Method of reducing craving in mammals |
US6245766B1 (en) | 1997-12-18 | 2001-06-12 | Pfizer Inc | Method of treating psychiatric conditions |
US6342515B1 (en) * | 1997-12-26 | 2002-01-29 | Dainippon Pharmaceutical Co., Ltd. | Remedy for neurodegenerative diseases |
WO1999037305A1 (en) | 1998-01-21 | 1999-07-29 | Glaxo Group Limited | Pharmaceutically active morpholinol |
US6274579B1 (en) | 1998-01-21 | 2001-08-14 | Glaxo Wellcome Inc. | Pharmaceutically active morpholinol |
US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
WO2000050020A2 (en) | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6323236B2 (en) | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6905708B2 (en) | 1999-02-26 | 2005-06-14 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
WO2000051546A2 (en) | 1999-03-01 | 2000-09-08 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
US6506799B1 (en) | 1999-04-01 | 2003-01-14 | Esperion Therapeutics, Inc. | Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds |
US20040106576A1 (en) | 1999-04-06 | 2004-06-03 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US20030055008A1 (en) | 1999-05-24 | 2003-03-20 | Marcotte David B. | Anticonvulsant derivatives useful in treating psychosis |
WO2000076493A1 (en) | 1999-06-14 | 2000-12-21 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
US20040002462A1 (en) | 1999-06-14 | 2004-01-01 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
WO2001001973A2 (en) | 1999-07-01 | 2001-01-11 | Pharmacia & Upjohn Company | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US20020025972A1 (en) | 1999-10-04 | 2002-02-28 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US6548551B2 (en) | 1999-10-04 | 2003-04-15 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6441038B1 (en) | 1999-10-12 | 2002-08-27 | Laxdale Limited | Treatment of fatigue, head injury and stroke |
WO2001026641A2 (en) | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030144271A1 (en) | 2000-01-22 | 2003-07-31 | Albert Shulman | Methods for the treatment of substance abuse |
US20020090615A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
WO2001062257A2 (en) | 2000-02-22 | 2001-08-30 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
US6713488B2 (en) | 2000-03-15 | 2004-03-30 | Sadee Wolfgang | Neutral antagonists and use thereof in treating drug abuse |
US6437147B1 (en) | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
WO2002009694A1 (en) | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
US20020037836A1 (en) | 2000-09-18 | 2002-03-28 | Henriksen Dennis Bang | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US6686337B2 (en) | 2000-10-30 | 2004-02-03 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
WO2003013524A1 (en) | 2001-08-09 | 2003-02-20 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20040242974A1 (en) | 2001-08-09 | 2004-12-02 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
WO2003092682A1 (en) | 2002-05-06 | 2003-11-13 | Eisai Co., Ltd. | Zonisamide use in obesity and eating disorders |
US20040033965A1 (en) | 2002-05-17 | 2004-02-19 | Gadde Kishore M. | Method for treating obesity |
WO2003097046A1 (en) | 2002-05-17 | 2003-11-27 | Duke University | Method for treating obesity |
US7425571B2 (en) * | 2002-05-17 | 2008-09-16 | Orexigen Therapeutics, Inc. | Method for treating obesity |
US20040198668A1 (en) | 2002-05-17 | 2004-10-07 | Duke University | Method for treating obesity |
US7109198B2 (en) * | 2002-05-17 | 2006-09-19 | Duke University | Method for treating obesity |
US20060009514A1 (en) | 2002-05-17 | 2006-01-12 | Gadde Kishore M | Method for treating obesity |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20050143322A1 (en) | 2002-05-17 | 2005-06-30 | Gadde Kishore M. | Method for treating obesity |
US20050137144A1 (en) | 2002-05-17 | 2005-06-23 | Gadde Kishore M. | Method for treating obesity |
WO2004009015A2 (en) | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
WO2004024096A2 (en) | 2002-09-13 | 2004-03-25 | Eisai Co., Ltd. | Method of treating tremors |
WO2004050020A2 (en) | 2002-11-27 | 2004-06-17 | Simon David L | Improved opioid pharmaceutical compositions |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US20060142290A1 (en) | 2003-04-29 | 2006-06-29 | Eckard Weber | Compositions for affecting weight loss |
US20040254208A1 (en) | 2003-04-29 | 2004-12-16 | Eckard Weber | Compositions for affecting weight loss |
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
WO2005000217A2 (en) | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
WO2004110368A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
US20050154002A1 (en) | 2003-07-23 | 2005-07-14 | Crooks Peter A. | Novel oral bioavailable prodrugs |
WO2005049043A1 (en) | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
US20050181070A1 (en) | 2004-01-13 | 2005-08-18 | Gadde Kishore M. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060079501A1 (en) | 2004-01-13 | 2006-04-13 | Krishnan K R R | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060100205A1 (en) | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
US20050277579A1 (en) | 2004-05-03 | 2005-12-15 | Ranga Krishnan | Compositions for affecting weight loss |
US20060058293A1 (en) | 2004-08-03 | 2006-03-16 | Eckard Weber | Combination of bupropion and a second compound for affecting weight loss |
WO2006017504A1 (en) | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
Non-Patent Citations (130)
Title |
---|
"A Novel Twist on Binge Eating Treatment" Primary Psychiatry; 6(10) 24-29 (1999). |
Altman and Bland. "Standard Deviations and Standard Errors," BMJ; 2005:331:903. |
Anderson, et al. Bupropion SR enhances weight loss Obesity R., vol. 10, N. 7, 2002, pp. 633-641, XP002351373. |
Appolinario et al. "Pharmacological Approaches in the Treatment of Binge Eating Disorder." Current Drug Targets; 5:301-307 (2004). |
Aronne, et al. "Weight Gain in the Treatment of Mood Disorders"; J Clin Psychiatry 2003;64 (supple 8). |
Asconape. "Some Common Issues in the Use of Antiepileptic Drugs." Seminars in Neurology; 22(1):27-39 (2002). |
Atkinson, Clinical Guidelines on the identification, Evaluation, and pharamacologic treatment of obesity in Adults, Online, Jul. 25, 2003, URL:http://www.endotext.org.obesity/obesity15b/obesity15b.htm. |
Ayala et al, "Weight Loss Associated With the Administration of Zonisamide", A Compendium of Posters and Platform Sessions for ZONEGRAN(TM) and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, Dec. 1-6, 2000, Los Angeles, California. |
Ayala et al, "Weight Loss Associated With the Administration of Zonisamide", A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, Dec. 1-6, 2000, Los Angeles, California. |
Ayala, "Weight Loss Associated With the Administration of Zonisamide", AES Proceedings, Epilepsia 41(Suppl. 7) :99 (2000)-No. 2.041. |
Beelen, et al. "Asymptomatic QTC prolongation associated with queitiapine fumarate overdose in a patient being treated with risperidone" Human & Experimental Toxicology 92001) 20, 215-219, (2001). |
Berke, et al., "Medical Management of Obesity", American Academy of Family Physicians, Jul. 15, 2000;62(2):419-26 ABSTRACT. |
Blanchard, et al., "Pancreatitis Treated with Didanosine and Tenofabir Disoproxil Fumarate" Clinical Infectious Diseases, 2003;37 pp. 57-62. |
Calabrese, et al. Letters to the Editors, "Lamotrigine and Clozapine for Bipolar Disorder" American J. of Psychiatry, vol. 157 9, Sep. 2000, 1523. |
Carlsen, et al. "Evidence for dissociation of insulin-and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease" Diabetes Research and Clinical Practice Amersterdam, vol. 39, No. 1, Jan. 1998, pp. 47-54. |
Carpenter, et al. "Mirtazapine Augmentation in the Treatment of Refractory Depression"; J Clin Psychiatry 60:1, Jan. 1999. |
Carroll, F.I. J. Med. Chem , 46:10 (2003). |
Cash, et al. "Attitudes about antidepressants: Influence of information about weight-related side effects"; Perceptual and Motor Skills, 2000, 90, 453-456. |
Chen, et al. "Synergistic Effects of Cannabiniod inverse agonist AM251 and opiod antagonist namefene on food intake" Brain Res. vol. 999, Jan. 2004, pp. 22-230. |
Chengappa, et al. "Changes in body Weight and Body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review" Clinical Therapeutics, 24 (10) 1576-1584 (2002). |
Clapham et al. (2001) Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacoloty & Therapeutics. 89:81-121. |
Cone, et al. "The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis,"Int'l Journal of Obesity, 25(5):S63-S67 (2001). |
Dechant et al. Drugs, 41:225-253 (1991). |
Dembowski, et al. "Successful Antimanic Treatment and Mood Stabilization with Lamotrigine, Clozapine, and Valproate in a Bipolar Patient after Lithium-induced Cerebellar Deterioration" Letter Pharmacopsychiatry, 2003; 36 83-86. |
Deshmukh, et al. "Managing weight gain as a side effect of antidepressant therapy"; Cleveland Clinic Journal or Medicine vol. 70, Jul. 7, 2003. |
Devlin, et al. Int. J. Eating Disord. 28:325-332 (2000). |
Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision, p. 583-595 (2000). |
Dursen, et al., Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia, Arch Gen Psychiatry vol. 56, Oct. 1999, 950-951. |
Dursun, et al. "Accelerated Weight Loss After Treating Refractory Depression with Fluoxetine Puls Topiramate: Possible Mechanism of Action" Canadian Journal of Psychiatry, vol. 46, No. 3 Apr. 2001, pp. 287-288. |
Dursun, et al. "Augmenting Antipsychotic treatment with Lamotrigine or topiramate in patients with treatment-resistant Schizophrenia: a naturalistic case-series outcome study" Journal of Psychopharmacology 15(4) 2001-297-301. |
Dursun, et al. "Lamotrgine-Clozapine Combination in Refractory Schizophrenia: Three Cases" J. Neuropsychiatry Clin. Neuroscience, 14:1, Winter 2002, 86. |
Dursun, et al., "Psychopharmacology for the Clinician Psychopharmacologie Pratiqu" Journal of Psychiatry Neuroscience, vol. 26 No. 2, 2001, 168. |
Erez et al. J. Med. Chem., 25:847-849 (1982). |
Erfuth, et al. "Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients", Neurophsychobiology, vol. 45, No. Supplement 1, Mar. 2002, pp. 33-36. |
Faught et al. "Randomized Controlled Trial of Zonisamide for the Treatment of Refractory Partial-Onset Seizures." Neurology; 57(10):1774-1779 (2001). |
Fava, Maurizio. "Weight Gain and Antidepresants"; J Clin Psychiatry 2000;61 (suppl 11). |
Fingl et al. The Pharmacological Basis of Theraputics. Ch.1, pp. 1. (1975). |
Fukagawa et al., "Monoaminergic anorectic agents", Nippon Yikurigaku Zasshi, Nov. 2001;118(5):303-8, 2001 ABSTRACT. |
Fuller et al., Fluoxetine: A Serotonergic Appetite Suppressant Drug, Drug Development Research, vol. 17, No. 1, 1989, pp. 1-15; XP009035038. |
Gadde and Logue, "Bupropion Sustained Release in Obesity: A Randomized Double-Blind, Placebo-Controlled Study", No. NR634, New Research Program & Abstracts, American Psychiatric Association, 1999 Annual Meeting, the Clinician, May 15-20, 1999, Washington, D.C. |
Gadde et al, "Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women", Obesity Research 9(9) :544-551 (2001). |
Gadde et al, "Randomized Controlled Trial of Zonisamide for Treating Obesity", American Epilepsy Society, http://164.109.45.39/submission/aes/status/..\preview.full.asp?presid=2%2E258, Sep. 11, 2002. |
Gadde et al, "Randomized Trial of Weight Loss Efficacy of Zonisamide", No. 304, 26(Suppl. 1), Aug. 2002, International Journal of Obesity and Related Metabolic Disorders, Journal of the International Association for the Study of Obesity, Ninth International Congress on Obesity, Sao Paolo, Brazil, Aug. 24-29, 2002. |
Gadde et al, "Zonisamide for Weight Loss in Obese Adults-A Randomized Controlled Trial", JAMA 289(14) :1820-1825 (2003). |
Gadde et al, "Zonisamide in Obesity: A 16-Week Randomized Trial", No. NR473, New Research, American Psychiatric Association 2002 Annual Meeting, May 18-23, 2002, Philadelphia, Pennsylvania. |
Gadde et al. Inpharma; 1383(84):9 (2003). |
Gatley, et al. European Journal of Pharmacolgy, 307:331-338 (1996). |
Gehlert D.R., et al., "The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding", J. Pharmacology and Experimental Therapeutics Oct. 1998;287(1):122-7 ABATRACT. |
Ginsberg and Sussman, "Effects of Mood Stabilizers on Weight", Primary Psychiatry 7(5):49-58 (2000). |
Glass et al. Neuropeptides, 33:360-368 (1999). |
Gordon, et al. "Mood Stablization and Weight Loss with Topiramate" American Journal of Psychiatry, American Psychiatric Association, Washington D.C. vol. 156, No. 6, Jun. 1999, pp. 968-969. |
Grady, "Quest for Weight-Loss Drug Takes an Unusual Turn", The New York Times-Health, www.nytimes.com, Mar. 15, 2003. |
Hahn, et al. J. Pharm Exper. Therapeutics 235:846-850. (1985). |
Harrison's Principles of Internal Medicine. Eleventh Edition, McGraw-Hill Book Company, p. 1921-1930 (1987). |
Hashiguti, et al. "Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis"; Journal of Neural Transmission (1993) 93:213-223. |
Hussey et al. J. Am. Chem. Soc., 125:3692-3693 (2003). |
International Search Report PCT/US03/15703, (2003). |
Islam, et al. Naltrexone, Serotonin Receptor Subtype Antagonists, and Carbohydrate Intake in Rats, Pharmacology Biochemistry and Behavior, vol. 48, No. 1, 1994, pp. 193-201; XP002292383. |
Jallon et al. Drug Safety; 24(13):969-978 (2004). |
Japanese Journal of Clinical Psychiatry (1987 16(1):123-132), and English-language version of Japanese Office Action citing the same (dated Oct. 28, 2008). |
Kanba et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18(4), 707-715 (1994). |
Kanios et al, "Compositions and methods for topical administration of pharmaceutically active agents", Database USPT on WEST-USP 5,719,197, Feb. 17, 1998. |
Kiptoo, et al. Enhancement of Transdermal delivery or 6-B-naltrexol via a codrug linked to hydroxyburpropion, Journal of Controlled Release 113 (2006) 137-145. |
Kirkham et al. Psychopharmacology 153:267-270(2001). |
Kirov, et al. Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case. BMC Psychiatry, 5:19, 8 pp. (2003). |
Klok et al. Macromolecules, 35:746-759 (2002). |
Kolb et al. A. Pharmaceutical Res., 6:266-271 (1985). |
Korner et al. "The emerging science of body weight regulation and its impact on obesity treatment," J. Clin. Invest., 111(5):565-570 (2003). |
Kossard, et al. Defining Urticarial Dermatitis; Arch Dermatol/vol. 142, Jan. 2006. |
Kushner, et al. "Obesity pharmacology: past, present, and future.", Current Opinion in Gastroenterology, Mar. 2002, pp. 213-220. |
Le Bourdonnec et al. J. Med. Chem., 43:2489-2492 (2000). |
Leppik et al. Epilepsy Research; 14:165-173 (1993). |
Lessig, et al., "Topiramate for Reversing Atypical Antipsychotic Weight Gain" J. Am. Child Adolesc. Psychiatry 40; Dec. 12, 2001. p. 1364. |
Levy, et al.,"Topiramate Produced Weight Loss Following Olanzapine-Induced Weight Gain in Schizophrenia" J. Clin. Psychiatry 63; Nov. 11, 2002, 1045. |
Malhotra, et al., "Medical Management of Obesity Associated With Mental Disorders", Journal or Clinical Psychiatry 2002;63[suppl 4]:24-32. |
Matsuura, "Indication for Anterior Temporal Lobectomy in Patients with Temporal Lobe Epilepsy and Psychopathology", Epilepsia 41(Suppl. 9) :39-42 (2000). |
McElroy et al. "Zonisamide in the Treatment of Binge-Eating Disorder: An Open-Label, Prospective Trial." J. Clin. Psychiatry; 65(1):50-56 (2004). |
McElroy et al. Inpharma; 1428:10 (2004). |
McLaughin, et al, Behavorial Pharmacology, 14:583:588 (2003). |
Michelson, et al., "Atomexetine in the Treatment of Children and Adolescents with Attention Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study", Pediatrics Nov. 2001;108(5):E83 ABSTRACT. |
Morris, III, "The Effect of Zonisamide Administration on Patient Weight", A Scientific Exhibit at the American Epilepsy Society Annual Meeting, Dec. 3, 2000, Los Angeles, California. |
Navarro, et al. "Topiramate for Clozapine-Induced Seizures" Am. J. Psychiatry 158; 6, Jun. 2001, 968-969. |
NDA20-789, ZONEGRAN (zonisamide) Capsules 100 mg, FDA Approved Labeling Text, p. 1-24 (Mar. 27, 2000). |
Ninan et al. Tetrahedron., 48:6709:16 (1992). |
Okada, et al. "Effects of zonisamide on dopaminergic system"; Epilepsy Research 22 (1995) 193-205. |
Okada, et al. "Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release" Epilepsy Research, 13 (1992) 113-119. |
Olsen, et al., "Conjugate Addition Ligands of Opioid Antagonists. Methacrylate Esters and Ethers of 6Alpha- And 6Beta-Naltrexol", Journal of Medicinal Chemistry, American Chemical Society, vol. 33:2, 1990, 737-741. |
Olszewski, et al. Evidence of Interactions Between Melanocortin and Opioid Systems in Regulation of Feeding, Neuroreort, vol. 12, No. 8, Jun. 13, 2001, pp. 1727-1730; XP009035026. |
Oommen et al. (1999) Zonisamide: A new antiepileptic drug. Clinical Neuropharmacology. 22(4):192-200. |
Parr et al. J. Immunol., 169:856-864 (2002). |
Pasternak et al. J. of Med. Chem., 23:674-676 (1980). |
Pavuluri, et al., Topiramate Plus Risperidone for Controlling Weight Gain and Symptoms in Preschool Mania, Journal of Child and Adolescent Psychopharmacology vol. 12 No. 3, 2002. p. 271-273. |
Penn, et al., "Pharmacotherapy of obesity in the near term.", Current Opinion in Endocrinology and Diabetes 2003 United States, 2003, pp. 311-316. |
Portoghese et al. J. Med. Chem., 29:1650-1653 (1986). |
Portoghese et al. J. Med. Chem., 29:1855-1861 (1986). |
Portoghese et al. Life Sci., 31:1283-1286 (1982). |
Portoghese, P.S. J. Med. Chem., 35:1927 (1992). |
Potter, et al. "Sustained Weight Loss Associated with 12-month topiramate Therapy" Epilepsia, Raven Press Ltd. New York, vol. 38, No. Suppl 8, 1997, p. 97. |
Remington's Pharmaceutical Sciences. 18th Edition; Easton, PA: Mack Publishing Co. (1990). |
Rotzinger et al., "Metabolism of some 'second' and 'fourth' generation antidepressants: iprindole, viloxazine, bupropin, mianserin, maprotiline, trazadone, nefazodone, and vanlafaxine.", Cellular and Molecular Neurobiology, 1999, 19, p. 430. |
Rowland, et al. Psychopharmacology, 159:111-116(2001). |
Sackellares et al. Epilepsia; 26(3):206-211 (1985). |
Saper et al. "The need to feed: Homeostatic and hedonic control of eating," Neuron, 36:199-211 (2002). |
Sashiwa et al. Macromolecules, 33:6913 (2000). |
Sayre et al. J. Med. Chem., 27:1325 (1984). |
Schmidhammer et al. A. Helv. Chim. Acta, 77:999 (1994). |
Schmidt et al. Epilepsy Research; 15:67-73 (1993). |
Shapira et al. "Treatment of Binge-Eating Disorder with Topiramate: A Clinical Case Series." J. Clin. Psychiatry; 61(5):368-371 (2000). |
Shapiro et al. "Additive Benefits of Combination Therapy with Sibutramine and Rimonabant on Body Weight, Insulin Sensitivity and Lipoproteins in Diet-Induced Obese Mice," 2005 NAASO Annual Meeting, Poster 405-P. |
Shelton, Richard C., "Classification of Antidepressants and their Clinical Implications" Primary Care Companion J. Clin. Psychiatry 2003-5 (Supp. 7) pp. 27-32. |
Spigset, et al. Therapeutic Approaches to Bulimia Nervosa, Expert Opinion on Therapeutic Patents, vol. 11, No. 3, 2001, pp. 463-477; XP002292382. |
Stepinski et al. Internat. J. of Peptide & Protein Res., 38:588-592 (1991). |
Stromberg, et al., "A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ehanol or sucrose using a limited-access procedure in rats." Pharmacology, Biochemistry, and Behavior, vol. 72, 483-490 (2002). |
Tamiz et al. J. Am. Chem. Soc., 122:5393-5394 (2000). |
Tamiz et al. J. Med. Chem., 44:1615:1622 (2001). |
Thearle, et al. "Obesity and Pharmacology" Endocrinology and Metabolism Clinics of North American W.B. Suanders Company, Philadelphia US vol. 32, No. 4, pp. 1005-1024. (2003). |
Tollefson, et al., Am J. Psychiatry, 154(5), 457-465 (1997). |
Tutka et al, "Convulsant and anticonvulsant effects of bupropion in mice", European Journal of Pharmacology, 2004, pp. 117-120. |
Vieta, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 64(7):834-839 (2003). |
Vieta, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. Journal of Clinical Psychopharmacology 24(4):374-378 (2004). |
Wadden et al. "Effects of Sibutramine Plus Orlistat in Obese Women Following 1 Year of Treatment by Sibutramine Alone: A Placebo-Controlled Trial," Obesity Research; 8(6):431 (2000). |
Walker et al, "Chronic Toxicity of the Anticonvulsant Zonisamide in Beagle Dogs", Fundamental and Applied Toxicology 11:333-342 (1988). |
Wang, et al., "Gabapentin augmentation therapy in bipolar depression" Bipolar Disorders 2002, 4; 296-301. |
Welty et al, "Weight Loss Associated With Use of Zonisamide in European and US Clinical Trials", A Compendium of Posters and Platform Sessions for Zonegran®, Presented at the Annual Meeting 2001 of the American Epilepsy Society, Nov. 30-Dec. 5, 2001, Philadelphia, Pennsylvania. |
Werneke, et al. Options for Pharmacological Management of Obesity in patients Treated with Atypical Antipsychotics, International Clinical Psychopharmacology, vol. 17 No. 4, 2002, pp. 145-160; XP009035036. |
Wilding. Current Drug Targets; 5:325-332 (2004). |
Wilner, "Is Weight Loss With Zonisamide Gender-Specific?", Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society, https://secure.neurohub.net/cgi-perl/get.cgi?pub=52318&ext=htm. |
Zeng, et al. Tetrahedron Lett. 29:5123 (1988). |
Zhang, et al. "Positional Cloning of the Mouse obese gen and its humane homologue" Nature 372:425-432 (1994). |
Zhu, et al. Pharmacologic Treatment of Easting Disorders, Canadian Journal of Psychiatry, vol. 47 No. 3, Apr. 3, 2002 pp. 227-234; XP009035028. |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
US8815889B2 (en) | 2005-11-22 | 2014-08-26 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US9457005B2 (en) | 2005-11-22 | 2016-10-04 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US9107837B2 (en) | 2006-06-05 | 2015-08-18 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8318788B2 (en) | 2006-11-09 | 2012-11-27 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
US9125868B2 (en) | 2006-11-09 | 2015-09-08 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
US8722085B2 (en) | 2006-11-09 | 2014-05-13 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
US10322121B2 (en) | 2010-01-11 | 2019-06-18 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
US11033543B2 (en) | 2010-01-11 | 2021-06-15 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
US10403170B2 (en) | 2012-06-06 | 2019-09-03 | Nalpropion Pharmaceuticals, Inc. | Methods of treating overweight and obesity |
US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US10231962B2 (en) | 2013-12-06 | 2019-03-19 | Nalpropion Pharmaceuticals, Inc. | Compositions and methods for reducing major adverse cardiovascular events |
US10231964B2 (en) | 2013-12-06 | 2019-03-19 | Nalpropion Pharmaceuticals, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9801875B2 (en) | 2013-12-06 | 2017-10-31 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Also Published As
Publication number | Publication date |
---|---|
EP1505967A1 (en) | 2005-02-16 |
US20050143322A1 (en) | 2005-06-30 |
US7425571B2 (en) | 2008-09-16 |
KR101072885B1 (en) | 2011-10-17 |
US20050137144A1 (en) | 2005-06-23 |
EP1505967A4 (en) | 2007-09-05 |
CN1320886C (en) | 2007-06-13 |
RU2341259C2 (en) | 2008-12-20 |
US20080188476A1 (en) | 2008-08-07 |
EP1505967B1 (en) | 2016-07-13 |
CA2483464C (en) | 2011-12-20 |
CN1652778A (en) | 2005-08-10 |
EP2301537A1 (en) | 2011-03-30 |
AU2003231788A1 (en) | 2003-12-02 |
CA2483464A1 (en) | 2003-11-27 |
US20040198668A1 (en) | 2004-10-07 |
US20080319036A1 (en) | 2008-12-25 |
MXPA04011203A (en) | 2005-07-14 |
KR20110043664A (en) | 2011-04-27 |
HK1074778A1 (en) | 2005-11-25 |
JP4545584B2 (en) | 2010-09-15 |
RU2004131636A (en) | 2005-06-27 |
AU2003231788B2 (en) | 2008-09-11 |
KR20050023265A (en) | 2005-03-09 |
US20040033965A1 (en) | 2004-02-19 |
WO2003097046A1 (en) | 2003-11-27 |
US7109198B2 (en) | 2006-09-19 |
US20060009514A1 (en) | 2006-01-12 |
JP2005530782A (en) | 2005-10-13 |
EP3173082A1 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7754748B2 (en) | Method for treating obesity | |
US20150320726A1 (en) | Method for treating obesity | |
US11033543B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
Fujioka | Safety and tolerability of medications approved for chronic weight management | |
US20190290618A1 (en) | Method for Treating Obesity | |
US20190262318A1 (en) | Method for Treating Obesity | |
Van der Westhuizen | Obesity: evidence-based pharmacy practice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DUKE UNIVERSITY, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GADDE, KISHORE M.;KRISHNAN, RANGA R.;REEL/FRAME:023052/0590 Effective date: 20030903 Owner name: DUKE UNIVERSITY,NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GADDE, KISHORE M.;KRISHNAN, K. RANGA R.;REEL/FRAME:023052/0590 Effective date: 20030903 Owner name: DUKE UNIVERSITY, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GADDE, KISHORE M.;KRISHNAN, K. RANGA R.;REEL/FRAME:023052/0590 Effective date: 20030903 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220713 |